Delaine Smith
Psychiatric/Mental Health · Topeka, KSNPI 1073589073
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,411, 3.3 times the $434 reported in 2021.
Across 242 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$661
- Lundbeck LLC$515
- AbbVie$492
- Teva Pharmaceuticals USA, Inc.$398
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$390
- Vanda Pharmaceuticals Inc.$374
- plus $2K from 10 others
What the payments were for
- Food & beverage$4,42599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 35 | $661 |
| Lundbeck LLC | 25 | $515 |
| AbbVie | 29 | $492 |
| Teva Pharmaceuticals USA, Inc. | 31 | $398 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $390 |
| Vanda Pharmaceuticals Inc. | 14 | $374 |
| Johnson & Johnson | 16 | $316 |
| Alkermes, Inc. | 15 | $307 |
| Neurocrine Biosciences, Inc. | 14 | $272 |
| E.r. Squibb & Sons, L.L.C. | 17 | $270 |
| Axsome Therapeutics, Inc. | 12 | $225 |
| Indivior Inc. | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Shockwave Medical, Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
How this compares
$4,472 in reported general payments places this provider in the 85th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 233 | $701,966 |
| Austedo XrDeutetrabenazine | 47 | $272,437 |
| IngrezzaValbenazine Tosylate | 28 | $218,345 |
| RexultiBrexpiprazole | 77 | $129,368 |
| VraylarCariprazine Hcl | 41 | $58,946 |
| Wellbutrin XlBupropion Hcl | 19 | $43,624 |
| LybalviOlanzapine/Samidorphan Malate | 23 | $36,646 |
| Aripiprazole | 155 | $16,468 |
| Asenapine Maleate | 57 | $16,320 |
| BelsomraSuvorexant | 36 | $15,460 |
| Clozapine | 296 | $15,229 |
| SaphrisAsenapine Maleate | 12 | $14,441 |
| Lurasidone Hcl | 50 | $13,745 |
| Paliperidone ErPaliperidone | 42 | $9,556 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 49 | $8,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $316 | $701,966233 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $398 | $272,43747 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $272 | $218,34528 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $661 | $129,36877 claims |
| AbbVieVraylar, Saphris | $492 | $73,38753 claims |
| Alkermes, Inc.Lybalvi | $307 | $36,64623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $68 | $7,34215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Topeka
- Rachelle BartelTopeka$8K
- Kerri MooreTopeka$7K
- Alicia SaderTopeka$7K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.